Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Authors:
- Javier MelchorJMJavier Melchor
- Marcos Garcia-LacarteMarcos Garcia-Lacarte
- Sara C. GrijalbaSGSara C. Grijalba
- Adrián Arnaiz-LechéAAAdrián Arnaiz-Leché
- Marién PascualMPMarién Pascual
- Carlos PanizoCPCarlos Panizo
- Oscar BlancoOBOscar Blanco
- Victor SeguraVSVictor Segura
- Francisco J. NovoFNFrancisco J. Novo
- Juan Garcia ValeroJVJuan Garcia Valero
- Patricia Pérez-GalánPPPatricia Pérez-Galán
- Jose A. Martinez-ClimentJMJose A. Martinez-Climent
Open Access
- 28 February 2023
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (2) , e006113
Abstract
Background: Approximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-cell malignancies and is currently being investigated in clinical trials for DLBCL. Whether BCL2 anti-apoptotic function represents a multifaceted vulnerability for DEL-DLBCL, affecting both lymphoma B cells and T cells within the tumor microenvironment, remains to be elucidated. Methods: Here, we present novel genetically engineered mice that preclinically recapitulate DEL-DLBCL lymphomagenesis, and evaluate their sensitivity ex vivo and in vivo to the promising combination of venetoclax with anti-CD20-based standard immunotherapy. Results: Venetoclax treatment demonstrated specific killing of MYC+/BCL2+ lymphoma cells by licensing their intrinsically primed apoptosis, and showed previously unrecognized immunomodulatory activity by specifically enriching antigen-activated effector CD8 T cells infiltrating the tumors. Whereas DEL-DLBCL mice were refractory to venetoclax alone, inhibition of BCL2 significantly extended overall survival of mice that were simultaneously treated with a murine surrogate for anti-CD20 rituximab. Conclusions: These results suggest that the combination of anti-CD20-based immunotherapy and BCL2 inhibition leads to cooperative immunomodulatory effects and improved preclinical responses, which may offer promising therapeutic opportunities for DEL-DLBCL patients.Keywords
This publication has 44 references indexed in Scilit:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell LymphomaCancer Cell, 2010
- Apoptotic signaling by c-MYCOncogene, 2008
- Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative studyBlood, 2008
- BCL2 protein expression parallels its mRNA level in normal and malignant B cellsBlood, 2004
- Control of Apoptosis in the Immune System: Bcl-2, BH3-Only Proteins and MoreAnnual Review of Immunology, 2003
- Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancerOncogene, 2001
- Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during LymphomagenesisMolecular and Cellular Biology, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesisGenes & Development, 1999